Moseley Investment Management Inc. Sells 788 Shares of Johnson & Johnson (NYSE:JNJ)

Moseley Investment Management Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 5.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,539 shares of the company’s stock after selling 788 shares during the quarter. Johnson & Johnson comprises approximately 1.0% of Moseley Investment Management Inc.’s portfolio, making the stock its 24th largest holding. Moseley Investment Management Inc.’s holdings in Johnson & Johnson were worth $2,125,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,071,642,000. Wellington Management Group LLP raised its stake in Johnson & Johnson by 16.4% in the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after purchasing an additional 3,391,657 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Johnson & Johnson by 16.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock valued at $3,453,978,000 after purchasing an additional 3,139,499 shares during the last quarter. Swedbank AB purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $331,178,000. Finally, Manning & Napier Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $229,824,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

Shares of Johnson & Johnson stock traded up $0.25 during trading on Thursday, reaching $158.73. 2,587,866 shares of the stock were exchanged, compared to its average volume of 7,326,564. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $382.01 billion, a price-to-earnings ratio of 9.90, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.39. The stock’s fifty day moving average is $151.88 and its 200 day moving average is $153.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period last year, the company earned $2.80 EPS. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.12%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. The Goldman Sachs Group cut their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 8th. Finally, TD Cowen reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.